Spruce Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Spruce Biosciences, Inc. (SPRB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $9.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-09
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $9.30M, a 342.86% increase from fiscal 2024.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $2.10M, a 47.50% decline from fiscal 2023.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $4.00M, a 110.53% increase from fiscal 2022.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $1.90M, a 34.48% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2025-12-31 | $9.30M 10-K · filed 2026-03-09 |
| 2024-12-31 | $2.10M 10-K · filed 2026-03-09 |
| 2023-12-31 | $4.00M 10-K · filed 2025-04-15 |
| 2022-12-31 | $1.90M 10-K · filed 2024-03-18 |
| 2021-12-31 | $2.90M 10-K · filed 2023-03-16 |
| 2020-12-31 | $600.00K 10-K · filed 2021-03-22 |
| 2019-12-31 | $100.00K 10-K · filed 2021-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |